Arrhythmia in acute heart failure

Acute Heart Failure

Volumn , Issue , 2008, Pages 221-234

  Chicos, Alexandru B ^a   Kadish, Alan H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56149126542     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-782-4_21     Document Type: Chapter

References (60)

1. Benza R, Tallaj J, Felker G, et al. The impact of arrhythmias in acute heart failure. J Card Fail 2004;10:279-84.
2. Adams K Jr, Fonarow G, Emerman C, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the fi rst 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
3. Fonarow G, Abraham W, Albert N, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZEHF): rationale and design. Am Heart J 2004;148: 43-51.
4. Ehrlich J, Nattel S, Hohnloser S. Atrial fi brillation and congestive heart failure: specifi c considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405.
5. Francis G. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Am J Cardiol 1986;57:3B-7B.
6. Holmes J, Kubo S, Cody R, et al. Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. Am Heart J 1985;110: 800-6.
7. Meinertz T, Hofmann T, Kasper W, et al. Signifi -cance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984;53: 902-7.
8. Doval H, Nul D, Grancelli H, et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation 1996;94:3198-203.
9. Singh S, Fisher S, Carson P, et al. Prevalence and signifi cance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol 1998;32:942-7.
10. Teerlink J, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifi cally predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000;101:40-6.
11. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287: 1531-40.
12. Burger A, Horton D, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8.
13. Cleland J, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-A survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24: 442-63.
14. Follath F, Cleland J, Just H, et al. Effi cacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
15. Gattis W, O'connor C, Gallup D, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43:1534-41.
16. Hasdai D, Topol E, Kilaru R, et al. Frequency, patient characteristics, and outcomes of mild-tomoderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fi brinolytic therapy trials. Am Heart J 2003;145:73-9.
17. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003; 41:204-10.
18. O'Connor C, Gattis W, Adams K Jr, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003;41:1452-7.
19. O'Connor C, Stough W, Gallup DS. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11:200-5.
20. Rudiger A, Harjola V, Muller A, et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 2005;7:662-70.
21. Torre-Amione G, Young J, Colucci Wet al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-7.
22. Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffi sance Cardiaque Avancee en Lorraine. J Am Coll Cardiol 1999;33:734-42.
23. Ravens U. Mechano-electric feedback and arrhythmias. Prog Biophys Mol Biol 2003;82:255-66.
24. Sachs F. Mechanoelectric transduction. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: Saunders; 2004:96-102.
25. Calaghan S, Belus A, White E. Do stretch-induced changes in intracellular calcium modify the electrical activity of cardiac muscle? Prog Biophys Mol Biol 2002;82:81-95.
26. Zabel M, Koller B, Sachs F, et al. Stretch-induced voltage changes in the isolated beating heart: importance of the timing of stretch and implications for stretch-activated ion channels. Cardiovasc Res 1996;32:120-30.
27. Janse M, Coronel R, Wilms-Schopman F, et al. Mechanical effects on arrhythmogenesis: from pipette to patient. Prog Biophys Mol Biol 2003;82: 187-95.
28. Chen R, Penny D, Greve G, et al. Stretch-induced regional mechanoelectric dispersion and arrhythmia in the right ventricle of anesthetized lambs. Am J Physiol Heart Circ Physiol 2004;286:H1008-14.
29. Hansen D, Borganelli M, Stacy GP, Jr, et al. Dosedependent inhibition of stretch-induced arrhythmias by gadolinium in isolated canine ventricles. Evidence for a unique mode of antiarrhythmic action. Circ Res 1991;69:820-31.
30. Bode F, Sachs F, Franz M. Tarantula peptide inhibits atrial fi brillation. Nature 2001;409:35-6.
31. Ausma J, Borgers M. Dedifferentiation of atrial cardiomyocytes: from in vivo to in vitro. Cardiovasc Res 2002;55(9-12).
32. Shi Y, Li D, Tardif J, et al. Enalapril effects on atrial remodeling and atrial fi brillation in experimental congestive heart failure. Cardiovasc Res 2002;54: 456-61.
33. Pogwizd S, Schlotthauer K, Li L, et al. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifi er potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001;88:1159-554.
34. Janse M. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 2004;61:208-17.
35. Nuss H, Kaab S, Kass D, et al. Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am J Physiol 1999;277: H80-H91.
36. Vermeulen J, McGuire M, Opthof T, et al. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res 1994;28:1547-54.
37. Aronson D, Burger A. Diabetes and the occurrence of ventricular arrhythmic events in patients with severe left ventricular dysfunction. Diabetologia 2002;45:1440-5.
38. Aronson D, Burger A. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysio 2003;26: 703-10.
39. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005;CD00:2230.
40. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
41. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
42. Packer M, Bristow M, Cohn J, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 1349-55.
43. Brodine W, Tung R, Lee J, et al. Effects of betablockers on implantable cardioverter defi brillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defi brillator Implantation Trial-II). Am J Cardiol 2005;96:691-5.
44. Aronson D, Burger A. Concomitant beta-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with decompensated heart failure. J Card Fail 2002;8:79-85.
45. Nieminen M, Bohm M, Cowie M, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
46. Mitchell L, Powell J, Gillis A, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defi -brillators (AVID) trial. J Am Coll Cardiol 2003;42: 81-7.
47. Vyas A, Guo H, Moss Aet al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defi brillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:769-73.
48. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
49. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
50. Ramires F, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-11.
51. Callans DJ, Josephson ME. Ventricular tachycardia in patients with coronary artery disease. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: Saunders; 2004:569-74.
52. Fuster V, Ryden L, Cannom D, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fi brillation-executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906.
53. Joglar J, Hamdan M, Ramaswamy K, et al. Initial energy for elective external cardioversion of persistent atrial fi brillation. Am J Cardiol 2000;86:348-50.
54. Wozakowska-Kaplon B, Janion M, Sielski J, et al. Effi cacy of biphasic shock for transthoracic cardioversion of persistent atrial fi brillation: can we predict energy requirements? Pacing Clin Electrophysiol 2004;27:764-8.
55. Chicos A, Mykytsey A, Lavi N, Avitall B. Atrial remodeling in an atrial fi brillation model without left ventricular systolic dysfunction. Heart Rhythm 2006;3(1S):S306.
56. Zipes D, Camm A, Borggrefe M, et al. ACC/AHA/ ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-346.
57. Cleland J, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-8.
58. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2005;112:IV1-203.
59. Harding J, Piacentino V III, Rothman S, et al. Prolonged repolarization after ventricular assist device support is associated with arrhythmias in humans with congestive heart failure. J Card Fail 2005;11: 227-32.
60. Ziv O, Dizon J, Thosani A, et al. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol 2005;45:1428-34.